{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T19:08:25Z","timestamp":1775329705905,"version":"3.50.1"},"reference-count":18,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T00:00:00Z","timestamp":1537488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007152","name":"Vivus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Increases in heart rate were seen during the clinical program for fixed-dose combination phentermine (PHEN) and topiramate (TPM), an oral medication indicated for weight management; however, the effect on cardiovascular (CV) outcomes is uncertain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The aim of the present study was to determine the extent to which the rates of major adverse CV events (MACE) in patients using PHEN and TPM (including fixed dose) differed from the MACE rates during unexposed periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>MarketScan, US insurance billing data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients or Other Participants<\/jats:title>\n                  <jats:p>Patients aged &amp;gt;18 years with \u22656 months of continuous enrollment in the database before taking PHEN and\/or TPM or after stopping these medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>PHEN and TPM, taken separately and together (including fixed dose).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>MACE, a composite of hospitalization for acute myocardial infarction and stroke and in-hospital CV death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Because the outcomes are rare and the duration of medication use was brief, few events occurred. The MACE rates among current users of PHEN\/TPM, fixed-dose PHEN\/TPM, and PHEN were lower than those among unexposed former users. In contrast, the rate of MACE among current users of TPM was greater than among unexposed former users [incidence rate ratio: PHEN\/TPM, 0.57; 95% CI, 0.19 to 1.78; fixed-PHEN\/TPM, 0.24; 95% CI, 0.03 to 1.70; PHEN, 0.56; 95% CI, 0.34 to 0.91; TPM, 1.58; 95% CI, 1.33 to 1.87).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, the data indicated no increased risk of MACE for current PHEN\/TPM users; however, the 95% CIs for the PHEN\/TPM groups were broad, indicating that the data were compatible with a wide range of possible values.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-01010","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T23:27:08Z","timestamp":1537572428000},"page":"513-522","source":"Crossref","is-referenced-by-count":37,"title":["Cardiovascular Safety During and After Use of Phentermine and Topiramate"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-9304","authenticated-orcid":false,"given":"Mary E","family":"Ritchey","sequence":"first","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abenah","family":"Harding","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Hunter","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Peterson","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Campbell, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip T","family":"Sager","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R","family":"Kowey","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"VIVUS, Inc., Campbell, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Thomas","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Cainzos-Achirica","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J","family":"Rothman","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Waltham, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth B","family":"Andrews","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary S","family":"Anthony","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2018,9,21]]},"reference":[{"key":"2020071700360563000_B1","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. Centers for Disease Control and Prevention; October 2017. Available at: https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db288.pdf. Accessed 10 July 2018."},{"issue":"9669","key":"2020071700360563000_B2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","article-title":"Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies","volume":"373","author":"Whitlock","year":"2009","journal-title":"Lancet"},{"key":"2020071700360563000_B3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DMSO.S95299","article-title":"Off-label drugs for weight management","volume":"10","author":"Hendricks","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"2","key":"2020071700360563000_B4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"9774","key":"2020071700360563000_B5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"2020071700360563000_B6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"2020071700360563000_B7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2020071700360563000_B8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pds.3310","article-title":"Validation of acute myocardial infarction in the Food and Drug Administration\u2019s Mini-Sentinel program","volume":"22","author":"Cutrona","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"2020071700360563000_B9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/pds.3434","article-title":"Estimation using all available covariate information versus a fixed look-back window for dichotomous covariates","volume":"22","author":"Brunelli","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2020071700360563000_B10","volume-title":"Modern epidemiology","author":"Rothman","year":"2008","edition":"3rd ed."},{"issue":"23","key":"2020071700360563000_B11","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"2020071700360563000_B12","unstructured":"Food and Drug Administration\n          . Guidance for industry and FDA staff. Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data. U.S. Department of Health and Human Services, Food and Drug Administration; May 2013. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM243537.pdf. Accessed 16 March 2018."},{"key":"2020071700360563000_B13","unstructured":"International Society for Pharmacoepidemiology\n          . Guidelines for good pharmacoepidemiology practices (GPP). Revision 3. International Society for Pharmacoepidemiology; June 2015. Available at: https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/. Accessed 10 August 2018."},{"key":"2020071700360563000_B14","unstructured":"European Medicines Agency\n          . Guideline on good pharmacovigilance practices (GVP). Module VIII \u2013 Post-authorisation safety studies (EMA\/813938\/2011 Rev 3). European Medicines Agency; 9 October 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129137.pdf. Accessed 16 March 2018."},{"key":"2020071700360563000_B15","unstructured":"European Medicines Agency\n          . Guideline on good pharmacovigilance practices (GVP). Module VI \u2013 Collection, management and submission reports of suspected adverse reactions to medicinal products (Rev 2). European Medicines Agency; 28 July 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2017\/08\/WC500232767.pdf. Accessed 14 March 2018."},{"issue":"5","key":"2020071700360563000_B16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.seizure.2014.02.007","article-title":"Patients with epilepsy are at an increased risk of subsequent stroke: a population-based cohort study","volume":"23","author":"Chang","year":"2014","journal-title":"Seizure"},{"issue":"9349","key":"2020071700360563000_B17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"2020071700360563000_B18","doi-asserted-by":"crossref","first-page":"e000208","DOI":"10.1161\/JAHA.113.000208","article-title":"Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings","volume":"2","author":"Patorno","year":"2013","journal-title":"J Am Heart Assoc"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/2\/513\/27378246\/jc.2018-01010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/2\/513\/27378246\/jc.2018-01010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T16:34:03Z","timestamp":1595003643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/2\/513\/5104461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,21]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01010","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,9,21]]}}}